Atlas market file · Equity · United States
Mesa Laboratories Inc /Co/MLAB
- Last close
- 101.01
- Change
- -1.57%
- 96-bar range
- 79.38 – 113.99
- As of
- 6 Aug 2026
Mesa Laboratories Inc /Co/ is an industrial instruments for measurement, display, and control issuer listed as MLAB on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
MLAB
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-25.64% over the window).
Source rail: Yahoo Finance chart API (MLAB). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for MLAB. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
MLAB public profile
Industrial instruments for measurement, display, and control issuer. Mesa Laboratories Inc /Co/ is connected to current market context, cited company sources and its retained research file.
Mesa Laboratories Inc /Co/ trades as MLAB on NASDAQ. Mesa Laboratories Inc /Co/ (MLAB) has a latest verified close of 101.01, down 1.57%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files MLAB under USA Stocks for browsing.
What changed for Mesa Laboratories Inc /Co/ today
Mesa Laboratories (MLAB) closed fiscal 2026 with $249.1M in revenue but a mere $6.7M net income, raising eyebrows over its ability to convert sales into profit. The company’s Clinical Genomics segment, which accounts for 80% of revenue from consumables, relies heavily on a concentrated customer base-a risky bet if any key client walks away.
MLAB’s operations span biopharmaceutical development and clinical diagnostics, with 35% of biopharma revenue tied to routine consumables. However, its $20.3M R&D spend and $4.4M inventory buildup contrast sharply with operating income of just $18.5M. Cash reserves sit at $26.9M, a figure that looks less comforting when stacked against $241.5M in liabilities.
Recent insider activity includes three separate 4 filings in June 2026, each detailing shares released from performance share units. This dilution cocktail arrives as the board approves non-compensation for director roles-a move that either signals skin-in-the-game or a management desks game of musical chairs with no payout.
Chart watchers have little to cling to: the evidence pack contains no technical analysis, and the company’s $427.7M asset base does little to clarify why its stock behaves like a lab rat in a maze. The real experiment here is whether MLAB can balance its genomic ambitions with a balance sheet that refuses to cooperate.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
MLAB technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on MLAB
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep MLAB research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
MLAB FAQ
What is Mesa Laboratories Inc /Co/ (MLAB)?Mesa Laboratories Inc /Co/ (MLAB) has a latest verified close of 101.01, down 1.57%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Mesa Laboratories Inc /Co/ (MLAB) has a latest verified close of 101.01, down 1.57%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for MLAB?Mesa Laboratories Inc /Co/ (MLAB) has a latest verified close of 101.01, down 1.57%, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Mesa Laboratories Inc /Co/ (MLAB) has a latest verified close of 101.01, down 1.57%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files MLAB under USA Stocks for browsing.
How often is the MLAB page updated?The MLAB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The MLAB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for MLAB?The MLAB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:MLAB. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The MLAB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:MLAB. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on MLAB?Yes. The workstation can open MLAB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open MLAB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this MLAB page investment advice?No. The MLAB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The MLAB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →